150 related articles for article (PubMed ID: 20404128)
21. Comparison of early and recent influenza A(H1N1)pdm09 isolates harboring or not the H275Y neuraminidase mutation, in vitro and in animal models.
Abed Y; Tu V; Carbonneau J; Checkmahomed L; Venable MC; Fage C; Marie-Ève-Hamelin ; Dufresne SF; Kobinger G; Boivin G
Antiviral Res; 2018 Nov; 159():26-34. PubMed ID: 30219318
[TBL] [Abstract][Full Text] [Related]
22. Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
Fage C; Tu V; Carbonneau J; Abed Y; Boivin G
Antivir Ther; 2017; 22(8):711-716. PubMed ID: 29082897
[TBL] [Abstract][Full Text] [Related]
23. Activity of the oral neuraminidase inhibitor A-322278 against the oseltamivir-resistant H274Y (A/H1N1) influenza virus mutant in mice.
Baz M; Abed Y; Nehmé B; Boivin G
Antimicrob Agents Chemother; 2009 Feb; 53(2):791-3. PubMed ID: 19015327
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of delayed treatment of China-made Peramivir with repeated intravenous injections in a mouse influenza model: from clinical experience to basal experiment.
Li Z; Li R; Li J; Xie H; Hao Y; Du Q; Chen T; Li Y; Chen R; Yang Z; Zhong N
BMC Infect Dis; 2016 Jul; 16():325. PubMed ID: 27392915
[TBL] [Abstract][Full Text] [Related]
25. Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.
Park S; Kim JI; Lee I; Lee S; Hwang MW; Bae JY; Heo J; Kim D; Jang SI; Kim H; Cheong HJ; Song JW; Song KJ; Baek LJ; Park MS
PLoS One; 2014; 9(7):e101325. PubMed ID: 24992479
[TBL] [Abstract][Full Text] [Related]
26. The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.
Abed Y; Bouhy X; L'Huillier AG; Rhéaume C; Pizzorno A; Retamal M; Fage C; Dubé K; Joly MH; Beaulieu E; Mallett C; Kaiser L; Boivin G
Antiviral Res; 2016 Aug; 132():6-12. PubMed ID: 27185624
[TBL] [Abstract][Full Text] [Related]
27. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.
McKimm-Breschkin JL; Rootes C; Mohr PG; Barrett S; Streltsov VA
J Antimicrob Chemother; 2012 Aug; 67(8):1874-83. PubMed ID: 22563014
[TBL] [Abstract][Full Text] [Related]
28. Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.
Tamura D; DeBiasi RL; Okomo-Adhiambo M; Mishin VP; Campbell AP; Loechelt B; Wiedermann BL; Fry AM; Gubareva LV
J Infect Dis; 2015 Oct; 212(8):1209-13. PubMed ID: 25943200
[TBL] [Abstract][Full Text] [Related]
29. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
[TBL] [Abstract][Full Text] [Related]
30. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Hurt AC; Ernest J; Deng YM; Iannello P; Besselaar TG; Birch C; Buchy P; Chittaganpitch M; Chiu SC; Dwyer D; Guigon A; Harrower B; Kei IP; Kok T; Lin C; McPhie K; Mohd A; Olveda R; Panayotou T; Rawlinson W; Scott L; Smith D; D'Souza H; Komadina N; Shaw R; Kelso A; Barr IG
Antiviral Res; 2009 Jul; 83(1):90-3. PubMed ID: 19501261
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of single intravenous injection of peramivir against influenza B virus infection in ferrets and cynomolgus macaques.
Kitano M; Itoh Y; Kodama M; Ishigaki H; Nakayama M; Ishida H; Baba K; Noda T; Sato K; Nihashi Y; Kanazu T; Yoshida R; Torii R; Sato A; Ogasawara K
Antimicrob Agents Chemother; 2011 Nov; 55(11):4961-70. PubMed ID: 21844317
[TBL] [Abstract][Full Text] [Related]
32. An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.
Kwon JJ; Choi WS; Jeong JH; Kim EH; Lee OJ; Yoon SW; Hwang J; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
J Gen Virol; 2018 Mar; 99(3):292-302. PubMed ID: 29493493
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812).
Sidwell RW; Bailey KW; Morrey JD; Wong MH; Baldwin TJ; Smee DF
Antiviral Res; 2003 Sep; 60(1):17-25. PubMed ID: 14516917
[TBL] [Abstract][Full Text] [Related]
34. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
[TBL] [Abstract][Full Text] [Related]
35. Peramivir for the treatment of influenza.
Shetty AK; Peek LA
Expert Rev Anti Infect Ther; 2012 Feb; 10(2):123-43. PubMed ID: 22339187
[TBL] [Abstract][Full Text] [Related]
36. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
37. Use of intravenous peramivir for treatment of severe influenza A(H1N1)pdm09.
Louie JK; Yang S; Yen C; Acosta M; Schechter R; Uyeki TM
PLoS One; 2012; 7(6):e40261. PubMed ID: 22768265
[TBL] [Abstract][Full Text] [Related]
38.
Jeong JH; Choi WS; Antigua KJC; Choi YK; Govorkova EA; Webby RJ; Baek YH; Song MS
J Virol; 2020 Dec; 95(1):. PubMed ID: 33055248
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment with baloxavir marboxil of a patient with peramivir-resistant influenza A/H3N2 with a dual E119D/R292K substitution after allogeneic hematopoietic cell transplantation: a case report.
Harada N; Shibata W; Koh H; Takashita E; Fujisaki S; Okamura H; Nanno S; Yamada K; Nakamae H; Hino M; Kakeya H
BMC Infect Dis; 2020 Jul; 20(1):478. PubMed ID: 32631240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
